object
earli
april
antimalari
drug
chloroquin
approv
emerg
treatment
coronaviru
diseas
unit
state
europ
although
infrequ
neuropsychiatr
symptom
report
patient
receiv
chloroquin
treatment
malaria
autoimmun
diseas
studi
investig
advers
event
ae
use
larg
selfreport
databas
conduct
disproportion
analysi
detect
neuropsychiatr
ae
signal
associ
use
chloroquin
hydroxychloroquin
report
faer
databas
fourth
quarter
fourth
quarter
adjust
report
odd
ratio
ror
develop
neuropsychiatr
ae
follow
use
chloroquin
calcul
use
multilevel
model
includ
ae
case
among
case
develop
neuropsychiatr
ae
follow
use
chloroquin
exposur
chloroquin
associ
statist
signific
high
report
amnesia
delirium
hallucin
depress
loss
conscious
lower
confid
interv
adjust
ror
although
degre
increas
ror
limit
statist
signific
high
report
neuropsychiatr
ae
includ
suicid
psychosi
confus
agit
conclus
current
pharmacovigil
studi
result
suggest
potenti
link
use
chloroquin
increas
risk
suicid
psychosi
confus
agit
would
inform
emerg
use
chloroquin
treatment
coronaviru
diseas
outbreak
global
emerg
situat
develop
drug
vaccin
intens
investig
worldwid
april
us
food
drug
administr
fda
european
medicin
agenc
ema
approv
use
chloroquin
hydroxychloroquin
emerg
treatment
base
potenti
effect
set
chloroquin
long
histori
treatment
malaria
autoimmun
diseas
safeti
efficaci
treatment
remain
unknown
treatment
malaria
autoimmun
diseas
chloroquin
caus
numer
side
effect
nausea
headach
pruritu
worsen
psoriasi
retinopathi
cardiac
dysfunct
neuropsychiatr
symptom
seizur
coma
psychosi
also
report
patient
receiv
chloroquin
still
unknown
neuropsychiatr
symptom
directli
associ
use
chloroquin
partli
rel
low
frequenc
understand
advanc
type
neuropsychiatr
symptom
may
occur
patient
treat
chloroquin
may
use
particularli
patient
intens
care
unit
rapid
clinic
judgement
requir
current
studi
investig
link
use
chloroquin
occurr
neuropsychiatr
symptom
use
fda
advers
event
report
system
faer
databas
provid
fda
sinc
databas
contain
larg
number
case
report
drug
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
doi
medrxiv
preprint
ae
wide
use
identifi
potenti
link
drug
ae
postmarket
surveil
drug
safeti
despit
risk
bia
associ
selfreport
data
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
doi
medrxiv
preprint
retrospect
pharmacovigil
studi
use
faer
databas
databas
contain
million
global
case
report
potenti
advers
event
drug
april
download
fda
websit
http
wwwfdagov
patient
data
report
fourth
quarter
fourth
quarter
faer
databas
contain
data
tabl
name
demo
drug
reac
outc
rpsr
ther
indi
mainli
use
follow
tabl
demo
provid
case
id
sex
age
year
event
occurr
countri
event
occurr
report
type
occup
eg
medic
doctor
pharmacist
lawyer
consum
reac
contain
advers
event
potenti
caus
drug
use
patient
drug
includ
name
dose
indic
date
administr
discontinu
drug
possibl
associ
ae
drug
tabl
causal
assess
relationship
drug
report
ae
classifi
report
primari
suspect
secondari
suspect
concomit
interact
analysi
includ
report
classifi
primari
suspect
secondari
suspect
reduc
risk
fals
posit
associ
deriv
conclus
addit
includ
report
report
medic
doctor
pharmacist
medic
staff
lawyer
consum
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
doi
medrxiv
preprint
duplic
report
exclud
latest
version
report
obtain
case
id
retain
faer
databas
ae
mainli
identifi
prefer
term
pt
determin
medic
dictionari
regulatori
activ
meddra
search
case
associ
chloroquin
includ
hydroxychloroquin
mefloquin
treatment
present
ae
interest
use
follow
neurolog
psychiatr
ae
term
summar
supplement
tabl
includ
mefloquin
one
drug
interest
antimalari
drug
known
caus
neuropsychiatr
ae
classifi
case
report
base
follow
binomi
factor
without
exposur
drug
interest
without
develop
ae
interest
irrespect
time
drug
administr
time
ae
develop
data
handl
statist
analys
perform
use
r
softwar
version
includ
drug
chloroquin
mefloquin
calcul
report
odd
ratio
ror
assess
potenti
druga
link
chloroquin
mefloquin
report
neuropsychiatr
symptom
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
doi
medrxiv
preprint
crude
ror
calcul
conting
tabl
describ
previous
report
classifi
two
factor
ae
term
drug
describ
lower
limit
confidenti
interv
ci
adjust
ror
ae
consid
significantli
highli
report
follow
use
drug
interest
compar
report
ae
follow
use
drug
calcul
ror
use
multilevel
model
adjust
covari
hierarch
design
inform
consent
requir
type
studi
work
conduct
accord
ethic
standard
laid
declar
helsinki
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
doi
medrxiv
preprint
total
analysi
includ
uniqu
case
report
case
report
exposur
chloroquin
lower
limit
ci
mefloquin
figur
neuropsychiatr
ae
except
somnol
show
high
report
adjust
ror
valu
higher
almost
case
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
doi
medrxiv
preprint
studi
investig
report
neuropsychiatr
ae
develop
follow
exposur
chloroquin
treatment
malaria
autoimmun
diseas
major
strength
studi
base
databas
includ
global
realworld
data
larg
number
patient
result
show
statist
signific
associ
albeit
margin
use
chloroquin
report
loc
amnesia
delirium
hallucin
depress
howev
statist
signific
associ
use
chloroquin
report
suicid
psychosi
confus
agit
suggest
link
use
chloroquin
increas
risk
ae
convers
mefloquin
show
associ
statist
signific
high
report
neuropsychiatr
ae
consist
earlier
literatur
report
studi
limit
result
use
selfreport
data
therefor
includ
bia
elimin
first
set
may
associ
report
bia
overor
underreport
neuropsychiatr
ae
follow
use
chloroquin
second
due
absenc
denomin
abl
discuss
incid
rate
neuropsychiatr
ae
third
multivari
adjust
consid
use
concomit
medic
medic
histori
patient
could
potenti
contribut
develop
worsen
neuropsychiatr
symptom
fourth
suicid
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
doi
medrxiv
preprint
includ
one
ae
analysi
possibl
suicid
case
repres
suicid
chloroquin
overdos
known
cardiotox
ae
chloroquin
fifth
includ
time
total
dose
chloroquin
mefloquin
analysi
lastli
possibl
final
dataset
includ
duplic
case
exclud
conclud
current
pharmacovigil
studi
use
faer
databas
suggest
potenti
link
use
chloroquin
increas
risk
suicid
psychosi
result
provid
inform
essenti
use
chloroquin
consid
treatment
patient
sinc
studi
base
selfreport
databas
inevit
contain
sever
bias
cohort
studi
need
valid
result
confirm
neuropsychiatr
safeti
chloroquin
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
studi
perform
use
fda
advers
event
report
system
faer
databas
provid
fda
inform
result
interpret
current
studi
repres
opinion
fda
studi
receiv
fund
author
potenti
conflict
interest
disclos
specif
regard
sanofi
sa
sell
plaquenil
hydroxychloroquin
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
doi
medrxiv
preprint
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
doi
medrxiv
preprint
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
mefloquin
b
number
report
ae
report
odd
ratio
adjust
base
age
sex
ae
ci
provid
adjac
tabl
note
horizont
axi
forest
plot
provid
logarithm
scale
ae
report
use
chloroquin
mefloquin
n
aror
calcul
appear
blank
abbrevi
ae
advers
event
aror
adjust
report
odd
ratio
loc
loss
conscious
am
alter
mental
statu
n
number
observ
lower
lower
limit
confid
interv
upper
upper
limit
confid
interv
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
